Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 25;20(3):2146.
doi: 10.3390/ijerph20032146.

Links between COVID-19 and Alzheimer's Disease-What Do We Already Know?

Affiliations
Review

Links between COVID-19 and Alzheimer's Disease-What Do We Already Know?

Ewa Rudnicka-Drożak et al. Int J Environ Res Public Health. .

Abstract

Alzheimer's disease (AD) is a life-changing condition whose etiology is explained by several hypotheses. Recently, a new virus contributed to the evidence of viral involvement in AD: the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the COVID-19 coronavirus disease. AD was found to be one of the most common COVID-19 comorbidities, and it was found to increase mortality from this disease as well. Moreover, AD patients were observed to present with the distinct clinical features of COVID-19, with delirium being prevalent in this group. The SARS-CoV-2 virus enters host cells through the angiotensin-converting enzyme 2 (ACE2) receptor. ACE2 is overexpressed in brains with AD, which thus increases the viral invasion. Furthermore, the inhibition of the ACE2 receptor by the SARS-CoV-2 virus may also decrease the brain-derived neurotrophic factor (BDNF), contributing to neurodegeneration. The ApoE ε4 allele, which increases the risk of AD, was found to facilitate the SARS-CoV-2 entry into cells. Furthermore, the neuroinflammation and oxidative stress existing in AD patients enhance the inflammatory response associated with COVID-19. Moreover, pandemic and associated social distancing measures negatively affected the mental health, cognitive function, and neuro-psychiatric symptoms of AD patients. This review comprehensively covers the links between COVID-19 and Alzheimer's disease, including clinical presentation, molecular mechanisms, and the effects of social distancing.

Keywords: Alzheimer’s disease; COVID-19; SARS-CoV-2; neuroinflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
A schematic representation of ACE/Ang II/AT1R and ACE2/Ang-(1-7)/Mas axes in AD and SARS-CoV-2 invasion with ACE2 receptor in the spotlight. The ACE2 receptor, through which SARS-CoV-2 enters cells, is upregulated in the brain with AD, which increases viral entry. Moreover, ACE2 transforms Aβ43 into Aβ42, which additionally intensifies the invasion of this virus. Solid arrows represent a transformation of one compound into other, and dotted arrows represent a ligand binding to the receptor. The dotted lines represent an effect caused by activation of the receptor and red lines represent inhibition. Abbreviations: Aβ—amyloid beta; ACE—angiotensin converting enzyme; AD—Alzheimer’s disease; Ang—angiotensin; ARBs—angiotensin receptor blockers; AT1R—angiotensin II type 1 receptor; BDNF—brain-derived neurotrophic factor; MasR – Mas receptor.

Similar articles

Cited by

References

    1. Dumurgier J., Sabia S. Nouvelles tendances épidémiologiques de la maladie d’Alzheimer [Epidemiology of Alzheimer’s disease: Latest trends] Rev Prat. 2020;70:149–151. (In French) - PubMed
    1. Garre-Olmo J. Epidemiologia de la enfermedad de Alzheimer y otras demencias [Epidemiology of Alzheimer’s disease and other dementias] Rev Neurol. 2018;66:377–386. (In Spanish) - PubMed
    1. Mendiola-Precoma J., Berumen L.C., Padilla K., Garcia-Alcocer G. Therapies for Prevention and Treatment of Alzheimer’s Disease. Biomed Res Int. 2016;2016:2589276. doi: 10.1155/2016/2589276. - DOI - PMC - PubMed
    1. Weller J., Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research. 2018;7:1161. doi: 10.12688/f1000research.14506.1. - DOI - PMC - PubMed
    1. Goodman R.A., Lochner K.A., Thambisetty M., Wingo T.S., Posner S.F., Ling S.M. Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011–2013. Alzheimers Dement. 2017;13:28–37. doi: 10.1016/j.jalz.2016.04.002. - DOI - PMC - PubMed

Substances